Cullinan Therapeutics, Inc.
CGEMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
CGEM Earnings Report
EPS Est: $-0.71 | FQ end 2026-06
How CGEM's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CLN-081 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Cullinan Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Cullinan Therapeutics, Inc.'s (CGEM) pipeline across Phase 2. Its lead program is CLN-081 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cullinan Therapeutics, Inc.'s next FDA catalyst?→
Cullinan Therapeutics, Inc.'s (CGEM) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGEM biotech catalysts?→
Add CGEM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cullinan Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.